AEST.MED.INT.HLD.SP.ADR/3 (3FMA) - Net Assets
Based on the latest financial reports, AEST.MED.INT.HLD.SP.ADR/3 (3FMA) has net assets worth €1.89 Million EUR (≈ $2.21 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€486.50 Million ≈ $568.77 Million USD) and total liabilities (€484.61 Million ≈ $566.56 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read 3FMA total debt and obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.89 Million |
| % of Total Assets | 0.39% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
AEST.MED.INT.HLD.SP.ADR/3 - Net Assets Trend (2021–2024)
This chart illustrates how AEST.MED.INT.HLD.SP.ADR/3's net assets have evolved over time, based on quarterly financial data. Also explore AEST.MED.INT.HLD.SP.ADR/3 total assets for the complete picture of this company's asset base.
Annual Net Assets for AEST.MED.INT.HLD.SP.ADR/3 (2021–2024)
The table below shows the annual net assets of AEST.MED.INT.HLD.SP.ADR/3 from 2021 to 2024. For live valuation and market cap data, see 3FMA market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €9.35 Million ≈ $10.93 Million |
-72.21% |
| 2023-12-31 | €33.63 Million ≈ $39.32 Million |
+126.72% |
| 2022-12-31 | €-125.88 Million ≈ $-147.17 Million |
+32.48% |
| 2021-12-31 | €-186.42 Million ≈ $-217.95 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to AEST.MED.INT.HLD.SP.ADR/3's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13362400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.23 Billion | 4033.90% |
| Total Equity | €30.46 Million | 100.00% |
AEST.MED.INT.HLD.SP.ADR/3 Competitors by Market Cap
The table below lists competitors of AEST.MED.INT.HLD.SP.ADR/3 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NextEnergy Solar Fund Ltd
LSE:NESF
|
$3.31 Million |
|
iTonic Holdings Ltd.
NASDAQ:ITOC
|
$3.31 Million |
|
Coloseum Holding a.s.
PR:COLOS
|
$3.31 Million |
|
BIOMIND LABS INC.
F:3XI
|
$3.31 Million |
|
McBride plc
LSE:MCB
|
$3.30 Million |
|
Love Group Global Ltd
AU:LVE
|
$3.30 Million |
|
Canada One Mining Corp
V:CONE
|
$3.30 Million |
|
Albion Enterprise VCT PLC
LSE:AAEV
|
$3.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AEST.MED.INT.HLD.SP.ADR/3's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 48,887,000 to 30,457,000, a change of -18,430,000 (-37.7%).
- Net loss of 19,945,000 reduced equity.
- Other factors increased equity by 1,515,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-19.95 Million | -65.49% |
| Other Changes | €1.51 Million | +4.97% |
| Total Change | €- | -37.70% |
Book Value vs Market Value Analysis
This analysis compares AEST.MED.INT.HLD.SP.ADR/3's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.28x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €-2.22 | €0.06 | x |
| 2022-12-31 | €-1.21 | €0.06 | x |
| 2023-12-31 | €0.34 | €0.06 | x |
| 2024-12-31 | €0.21 | €0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AEST.MED.INT.HLD.SP.ADR/3 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -65.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.64%
- • Asset Turnover: 1.55x
- • Equity Multiplier: 15.96x
- Recent ROE (-65.49%) is below the historical average (-35.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -90.87% | 1.12x | 0.00x | €-570.95 Million |
| 2022 | 0.00% | -11.38% | 1.23x | 0.00x | €-64.88 Million |
| 2023 | -76.57% | -5.48% | 1.22x | 11.47x | €-42.32 Million |
| 2024 | -65.49% | -2.64% | 1.55x | 15.96x | €-22.99 Million |
Industry Comparison
This section compares AEST.MED.INT.HLD.SP.ADR/3's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $6,529,088,395
- Average return on equity (ROE) among peers: -82.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AEST.MED.INT.HLD.SP.ADR/3 (3FMA) | €1.89 Million | 0.00% | 256.41x | $3.30 Million |
| China Resources Medical Holdings Company Limited (1PH) | $7.01 Billion | 3.67% | 0.95x | $428.88 Million |
| JINXIN FERT.GRP HD-00001 (3NX) | $10.35 Billion | 2.73% | 0.45x | $720.78 Million |
| REVITALIST L.A.W. LTD (4DO) | $1.87 Million | -771.24% | 4.54x | $744.60K |
| Wenzhou Kangning Hospital Co. Ltd (4WK) | $1.34 Billion | 4.88% | 1.24x | $19.18 Million |
| Bumrungrad Hospital Public Company Limited (BZ7A) | $24.10 Billion | 29.08% | 0.21x | $49.31K |
| Eifelhöhen-Klinik AG (EIF) | $9.88 Million | -19.11% | 6.64x | $8.99 Million |
| Fresenius Medical Care AG & Co. KGaA (FME) | $2.01 Billion | -12.28% | 1.84x | $12.02 Billion |
| Fresenius Medical Care AG & Co. KGaA (FMEA) | $10.83 Billion | 11.82% | 1.22x | $11.58 Billion |
| Fresenius SE & Co. KGaA (FRE) | $3.10 Billion | 10.64% | 3.84x | $27.16 Billion |
About AEST.MED.INT.HLD.SP.ADR/3
Aesthetic Medical International Holdings Group Limited provides aesthetic medical services in the People's Republic of China. The company offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments, including minimally invasive and energy-based treatments, which include laser, ultrasound, and radiofrequency tr… Read more